| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,492 |
7,876 |
$456K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,936 |
1,762 |
$156K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,102 |
1,023 |
$147K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,548 |
1,396 |
$114K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,164 |
998 |
$94K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,741 |
1,582 |
$79K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
974 |
845 |
$72K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
666 |
556 |
$55K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
431 |
408 |
$32K |
| 96160 |
|
1,423 |
1,239 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
961 |
820 |
$16K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
202 |
165 |
$13K |
| 90686 |
|
1,308 |
1,184 |
$13K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
875 |
768 |
$11K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
220 |
150 |
$6K |
| 90734 |
|
401 |
293 |
$6K |
| 90651 |
|
249 |
180 |
$5K |
| 0072A |
|
124 |
118 |
$5K |
| 0001A |
|
117 |
117 |
$5K |
| 0071A |
|
117 |
107 |
$5K |
| 0002A |
|
103 |
102 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
118 |
116 |
$4K |
| 80061 |
Lipid panel |
407 |
297 |
$3K |
| 90620 |
|
151 |
99 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
100 |
99 |
$2K |
| 90670 |
|
215 |
171 |
$2K |
| 90716 |
|
98 |
68 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
94 |
93 |
$2K |
| 85018 |
|
761 |
615 |
$2K |
| 90707 |
|
128 |
96 |
$2K |
| 82947 |
|
410 |
299 |
$1K |
| 90715 |
|
82 |
68 |
$984.84 |
| 0003A |
|
16 |
16 |
$674.24 |
| 99406 |
|
67 |
60 |
$537.34 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
35 |
32 |
$507.50 |
| 90647 |
|
66 |
54 |
$462.06 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
16 |
16 |
$405.36 |
| 90696 |
|
12 |
12 |
$381.00 |
| 90723 |
|
44 |
42 |
$345.75 |
| 90633 |
|
30 |
30 |
$192.00 |
| 90672 |
|
13 |
12 |
$83.20 |
| 36415 |
Collection of venous blood by venipuncture |
19 |
19 |
$77.90 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
13 |
$0.75 |
| 99072 |
|
479 |
363 |
$0.00 |
| 1033F |
|
62 |
56 |
$0.00 |
| 99177 |
|
16 |
16 |
$0.00 |
| 4000F |
|
62 |
56 |
$0.00 |
| 96161 |
|
14 |
14 |
$0.00 |